Hep C Coalition response to Cochrane Review
The response addresses the considerable shortcomings and scientific errors, calling on the Collaboration to immediately publish clarifications of their findings. The response says:
“We urge the Cochrane Collaboration immediately to publish clarification of their findings emphasising that the studies, as structured, cannot possibly draw any conclusions as to morbidity and mortality or other hard end points due to their short-term nature. The fact of virological cure is there and a statement as to the substantial other body of evidence showing that successfully treating hepatitis C does change outcomes should be included. We are sure that the Cochrane Collaboration would wish to avoid the situation where their work could lead to enhanced morbidity and mortality from a curable disease and we would be happy to help draft such clarification and provide any supporting evidence required.”
The Hepatitis C Coalition is a group of leading clinicians, patient organisations, professional groups, industry and other interested parties (including Blenheim) committed to the reduction of morbidity and mortality associated with hepatitis C and its eventual elimination. The Hepatitis C Coalition has funding from AbbVie, Gilead Sciences and Merck Sharp & Dohme. For more information, please visit their website.